Amplify Treatments, Testing and Advancements ETF
  
Schedule of Investments
  
as of June 30, 2024 (Unaudited)
  
   
COMMON STOCKS - 98.8%
  
Shares
    
Value
  
Health Care - 98.8%(a)
        
Abbott Laboratories
    
782
    
$
81,258
  
AbbVie, Inc.
    
484
      
83,016
  
Adaptive Biotechnologies Corp.(b)
    
32,229
      
116,669
  
Alnylam Pharmaceuticals, Inc.(b)
    
3,931
      
955,233
  
AN2 Therapeutics, Inc.(b)
    
6,614
      
14,220
  
Arbutus Biopharma Corp.(b)
    
41,271
      
127,527
  
Arcturus Therapeutics Holdings, Inc.(b)
    
5,890
      
143,421
  
AstraZeneca PLC - ADR
    
1,009
      
78,692
  
                 
Atea Pharmaceuticals, Inc.(b)
    
18,419
      
60,967
  
BioCryst Pharmaceuticals, Inc.(b)
    
45,134
      
278,928
  
BioNTech SE - ADR(b)
    
5,765
      
463,275
  
Bio-Rad Laboratories, Inc. - Class A(b)
    
1,354
      
369,791
  
CEL-SCI Corp.(b)(d)
    
12,009
      
13,930
  
Chimerix, Inc.(b)
    
19,874
      
17,410
  
CorMedix, Inc.(b)
    
12,024
      
52,064
  
Cue Biopharma, Inc.(b)
    
10,786
      
13,375
  
CureVac NV(b)(d)
    
49,054
      
166,784
  
Dynavax Technologies Corp.(b)
    
28,625
      
321,459
  
Eli Lilly and Co.
    
97
      
87,822
  
Emergent BioSolutions, Inc.(b)
    
11,460
      
78,157
  
Enanta Pharmaceuticals, Inc.(b)
    
4,632
      
60,077
  
Fulgent Genetics, Inc.(b)
    
6,544
      
128,393
  
Gilead Sciences, Inc.
    
1,277
      
87,615
  
Gritstone bio, Inc.(b)
    
24,074
      
14,875
  
GSK PLC - ADR
    
1,963
      
75,575
  
HilleVax, Inc.(b)
    
10,874
      
157,238
  
ImmunityBio, Inc.(b)(d)
    
64,255
      
406,092
  
Immunocore Holdings PLC - ADR(b)
    
9,166
      
310,636
  
InflaRx NV(b)
    
13,057
      
22,719
  
Inovio Pharmaceuticals, Inc.(b)
    
5,746
      
46,425
  
Invivyd, Inc.(b)
    
26,457
      
29,103
  
Johnson & Johnson
    
557
      
81,411
  
Labcorp Holdings, Inc.
    
2,958
      
601,983
  
Merck & Co., Inc.
    
625
      
77,375
  
Moderna, Inc.(b)
    
3,794
      
450,537
  
Novavax, Inc.(b)
    
20,011
      
253,339
  
Ocugen, Inc.(b)(d)
    
56,282
      
87,237
  
OPKO Health, Inc.(b)(d)
    
152,428
      
190,535
  
OraSure Technologies, Inc.(b)
    
16,175
      
68,906
  
Pfizer, Inc.
    
2,831
      
79,211
  
Quest Diagnostics, Inc.
    
4,115
      
563,261
  
QuidelOrtho Corp.(b)
    
9,190
      
305,292
  
Regeneron Pharmaceuticals, Inc.(b)
    
81
      
85,133
  
Renovaro, Inc.(b)(d)
    
32,708
      
57,239
  
Sanofi SA - ADR
    
1,647
      
79,912
  
Scilex Holding Co.(b)
    
1
      
2
  
SIGA Technologies, Inc.
    
15,554
      
118,055
  
Takeda Pharmaceutical Co. Ltd. - ADR
    
6,025
      
77,964
  
Vaxart, Inc.(b)
    
39,212
      
26,166
  
Vaxcyte, Inc.(b)
    
5,397
      
407,527
  
Vir Biotechnology, Inc.(b)
    
29,755
      
264,820
  
XBiotech, Inc.(b)
    
6,754
      
34,716
  
Zai Lab, Ltd. - ADR(b)
    
20,595
      
356,911
  
             
9,130,278
  
TOTAL COMMON STOCKS (Cost $19,676,183)
      
9,130,278
  
                 
RIGHTS - 0.0%(e)
  
Contracts
    
Value
  
AstraZeneca PLC - CVR(b)(c)
    
11,792
      
0
  
Gurnet Point Capital LLC, Expires 09/23/2024, Exercise Price $0.85(b)(c)
    
16,557
      
0
  
TOTAL RIGHTS (Cost $0)
      
0
  
                 
SHORT-TERM INVESTMENTS - 10.7%
  
Shares
          
Investments Purchased with Proceeds from Securities Lending - 9.9%
                
First American Government Obligations Fund - Class X, 4.65%(f)
    
919,607
      
919,607
  
                 
Money Market Funds - 0.8%
                
Invesco Government & Agency Portfolio - Institutional Class, 5.25%(f)
    
70,636
      
70,636
  
TOTAL SHORT-TERM INVESTMENTS (Cost $990,243)
      
990,243
  
                 
TOTAL INVESTMENTS - 109.5% (Cost $20,666,426)
    
$
10,120,521
  
Liabilities in Excess of Other Assets - (9.5)%
      
(881,986
)
TOTAL NET ASSETS - 100.0%
          
$
9,238,535
  
               
Percentages are stated as a percent of net assets.
          
   
The Global Industry Classification Standard ("GICS®") was developed by and/or is the exclusive property of MSCI, Inc. ("MSCI") and Standard & Poor’s Financial Services LLC (“S&P”). GICS® is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services.
  

ADR - American Depositary Receipt
CVR – Contingent Value Right
NV - Naamloze Vennootschap
PLC - Public Limited Company
SA - Sociedad Anónima

(a)
To the extent that the Fund invests more heavily in a particular industry or sector of the economy, its performance will be especially sensitive to developments that significantly affect those industries or sectors.
(b)
Non-income producing security.
(c)
Fair value determined using significant unobservable inputs in accordance with procedures established by and under the supervision of the Adviser, acting as Valuation Designee. These securities represented $0 or 0.0% of net assets as of June 30, 2024.
(d)
All or a portion of this security is on loan as of June 30, 2024. The total market value of these securities was $856,798 which represented 9.3% of net assets.
(e)
Represents less than 0.05% of net assets.
(f)
The rate shown represents the 7-day effective yield as of June 30, 2024.


Summary of Fair Value Disclosure as of June 30, 2024 (Unaudited)
 
Amplify Treatments, Testing and Advancements ETF has adopted authoritative fair value accounting standards which establish an authoritative definition of fair value and set out a hierarchy for measuring fair value. These standards require additional disclosures about the various inputs and valuation techniques used to develop the measurements of fair value, a discussion of changes in valuation techniques and related inputs during the period, and expanded disclosure of valuation levels for major security types. These inputs are summarized in the three broad levels listed below. The inputs or methodology used for valuing securities are not an indication of the risk associated with investing in those securities.
 
Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities that the Fund has the ability to access.
 
Level 2 - Observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument on an inactive market, prices for similar instruments, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data.
 
Level 3 - Unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available, representing the Fund’s own assumptions about the assumptions a market participant would use in valuing the asset or liability, and would be based on the best information available.
 
The following is a summary of the fair valuation hierarchy of the Fund’s securities as of June 30, 2024:

   
Level 1
    
Level 2
    
Level 3
    
Total
  
Investments:
                        
  Common Stocks
    
9,130,278
      
–
      
--
      
9,130,278
  
  Rights
    
–
      
–
      
0
(a) 
    
0
(a) 
  Investments Purchased with Proceeds from Securities Lending
    
919,607
      
–
      
–
      
919,607
  
  Money Market Funds
    
70,636
      
–
      
–
      
70,636
  
Total Investments
    
10,120,521
      
–
      
0
(a) 
    
10,120,521
  
   
Refer to the Schedule of Investments for additional information.
  

(a)
Amount is less than $0.50.

GERM
  
Balance as of 09/30/2023
    
Amortization/
Accretion
    
Net Realized Gain (Loss)
    
Net Change in
Unrealized
Appreciation
(Depreciation)
    
Purchases/
Acquisition
    
Sales
    
Corporate Action
    
Transfer In/
Out of Level 3
    
Balance as of 06/30/2024
    
Net Change in
Unrealized
Appreciation
(Depreciation) on
Securities held at
06/30/2024
  
Rights
  
$
1,324
    
$
-
    
$
-
    
$
(1,324
)
  
$
-
    
$
-
    
$
-
    
$
-
    
$
-
    
$
(1,324
)

The following is a summary of quantitative information about Level 3 Fair Value Measurements:
           
                          
GERM
  
Fair Value as of
06/30/2024
  
Valuation Techniques
Unobservable Input
  
Range/Weighted
Average
Unobservable Input
  
Impact to Valuation from
an Increase to Input
  
Rights (AstraZeneca)
  
$
0
  
Market Approach
No Market Activity
    
-
  
Increase
  
Rights (Gurnet Point Capital LLC)
  
$
0
  
Market Approach
No Market Activity
    
-
  
Increase
  
                              

Secured Borrowings (Unaudited) The Funds adopted guidance requiring entities to present gross obligations for secured borrowings by the type of collateral pledged and remaining time to maturity. As of June 30, 2024, the Fund had loaned securities and received cash collateral for the loans. The cash collateral is invested by the Securities Lending Agent in accordance with approved investment guidelines. Those guidelines require the cash collateral to be invested in readily marketable, high quality, short-term obligations; however, such investments are subject to risk of payment delays or default on the part of the issuer or counterparty or otherwise may not generate sufficient interest to support the costs associated with securities lending. The Fund could also experience delays in recovering its securities and possible loss of income or value if the borrower fails to return the borrowed securities, although the Fund is indemnified from this risk by contract with the Securities Lending Agent.